Pharming Group N.V.
PHAR
$11.72
-$0.63-5.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 24.52% | -32.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.52% | -32.00% | |||
| Cost of Revenue | 118.92% | -68.56% | |||
| Gross Profit | 14.99% | -22.95% | |||
| SG&A Expenses | -4.43% | -10.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -277.72% | -8.33% | |||
| Total Operating Expenses | 14.92% | -25.26% | |||
| Operating Income | 126.74% | -262.13% | |||
| Income Before Tax | 163.95% | -199.04% | |||
| Income Tax Expenses | 205.45% | 186.93% | |||
| Earnings from Continuing Operations | 131.42% | -197.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 131.42% | -197.84% | |||
| EBIT | 126.74% | -262.13% | |||
| EBITDA | 248.91% | -128.79% | |||
| EPS Basic | 135.71% | -187.50% | |||
| Normalized Basic EPS | 172.50% | -366.67% | |||
| EPS Diluted | 135.71% | -197.22% | |||
| Normalized Diluted EPS | 172.50% | -407.69% | |||
| Average Basic Shares Outstanding | -10.56% | 12.41% | |||
| Average Diluted Shares Outstanding | -10.56% | -1.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||